TerminatedPhase 3

Duobrii Treatment of Acne Keloidalis Nuchae (AKN)

Stopped: Interim analysis did not show any significant differences between groups

United States15 participantsStarted 2022-10-26

Plain-language summary

Acne keloidalis nuchae (AKN) is one of the chronic forms of scarring folliculitis, affecting predominantly the occipital scalp, seen mostly in men of African descent. Duobrii has the advantage of being the only high potency topical steroid-retinoid combination approved by the FDA with dermatologic indication. Researchers are proposing the off-labeled use of Duobrii for the management of early-mild AKN. The research team hypothesizes that subjects will experience significant clinical improvement in lesion counts. Patients will be followed with visits scheduled at baseline, 4 weeks, 8 weeks, and 12 weeks. During these in-clinic visits, there will be surveys regarding the severity of AKN symptoms, photographs, and clinical assessments.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Male or female subject at least 18 years of age * Subject is able to provide written informed consent and comply with the requirements of this study protocol * Subjects have AKN class I or II (less than 6.5 cm in width) * Subjects who are women of childbearing potential (WOCBP) must have a negative urine pregnancy test at screening and must be practicing an adequate and medically acceptable method of birth control for at least 30 days prior to Day 0 and at least 6 months after the last dose of study. Acceptable methods of birth control include: * intrauterine device (IUD) oral; * transdermal; * implanted or injected hormonal contraceptives (must have been initiated at least 1 month before entering the study); * tubal ligation; * abstinence; * barrier methods with spermicide. * If not of child-bearing potential, subjects must have: * a sterile or vasectomized partner; * have had a hysterectomy; * a bilateral oophorectomy or be clinically diagnosed infertile; * or be in a menopausal state for at least a year. * Subject is judged to be in good general health as determined by the principal investigator. Exclusion Criteria: * unable to understand and provide written consent * Have received prior intralesional steroids for AKN within the past 6 months * Are using topical steroids or topical medications on their scalp within 4 weeks * Have used Duobrii on the scalp for AKN or other scalp disorders * Subject is pregnant or breastfeedin…

What they're measuring

Change in Lesion Count

Timeframe: Baseline and Week 12

Trial details

NCT IDNCT05608499

SponsorIcahn School of Medicine at Mount Sinai

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-04-15

Results submitted2025-10-01